期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
哌柏西利联用来曲唑对比多西他赛联用表柔比星一线治疗晚期乳腺癌的循证药物经济学评价
1
作者 彭词艳 陈景 +2 位作者 李斯妮 李健和 彭六保 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2023年第3期214-222,共9页
2015年哌柏西利(Palbociclib)成为首个被FDA批准的CDK4/6选择性小分子酪氨酸激酶抑制剂(TKI)。CDK4/6抑制剂对于晚期HR+/HER2-乳腺癌患者来说,在阻止肿瘤生长、阻止疾病发展和提高存活率方面显示出显著的效果。本研究通过贝叶斯Meta分析... 2015年哌柏西利(Palbociclib)成为首个被FDA批准的CDK4/6选择性小分子酪氨酸激酶抑制剂(TKI)。CDK4/6抑制剂对于晚期HR+/HER2-乳腺癌患者来说,在阻止肿瘤生长、阻止疾病发展和提高存活率方面显示出显著的效果。本研究通过贝叶斯Meta分析和Markov模型评价哌柏西利联用来曲唑对比多西他赛联用表柔比星一线治疗晚期乳腺癌的有效性和经济性。结果显示,多西他赛联用表柔比星对比哌柏西利联用来曲唑治疗晚期HR+/HER2-乳腺癌的无进展生存期(progression-free survival, PFS)为HR=1.8, 95%CI=0.49~5.68, P <0.1,总生存期(Overall Survival, OS)为HR=1.5,95%CI=0.62~5.90, P <0.1;哌柏西利联用来曲唑组获得3.55 LYs,比多西他赛联用表柔比星组增加了0.68 LYs。ICER为91 494元·QALY–1,低于全国的WTP (161 940元·QALY–1),敏感性分析结果与基本分析结果基本一致,说明基础分析结果较为稳定。哌柏西利联用来曲唑对比多西他赛联用表柔比星一线治疗晚期乳腺癌疗效更好,更具有经济性,值得临床关注。 展开更多
关键词 哌柏西利 来曲唑 多西他赛 表柔比星 乳腺癌 贝叶斯Meta分析 药物经济学评价
原文传递
Study of the economic burden and influencing factors on stroke patients in Central China in the post-epidemic era 被引量:1
2
作者 ciyan peng Jing Chen +2 位作者 Sini Li Jianhe Li Liubao peng 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2022年第7期545-555,共11页
The economic burden of disease is the main burden of disease for patients,and experts and scholars have done various studies from different perspectives on various types of diseases.In the present study,we focused on ... The economic burden of disease is the main burden of disease for patients,and experts and scholars have done various studies from different perspectives on various types of diseases.In the present study,we focused on the basic situation of hospitalization cost of stroke patients in Hunan Province and analyzed the factors affecting the hospitalization cost of stroke patients.A retrospective random sample of 7270-case home data of patients discharged from several hospitals in Hunan Province with diagnoses of ICD-10 codes I60 to I64 from 2019 to 2021 was used to analyze the patient’s hospitalization costs and the influencing factors.The univariate analysis was used to eliminate irrelevant factors,and multiple linear regression analysis was performed on the effective factors.Patients’medical costs are increasing year by year,with drug costs accounting for a high proportion of patients’hospitalization costs.The ranking of the total effect factors of hospitalization costs was as follows:the number of days of hospitalization,the level of the institution,the disease subtype,gender,the type of participation,and age.It was recommended to strengthen the scientific and rational use of drugs,improve medical technology and service level,do a good job in early screening and prevention of diseases,realize the hierarchical diagnosis and treatment system,play an active role in community hospitals,use medical resources rationally,develop scientific and rational treatment plans,shorten the number of days of hospitalization,control costs effectively,strengthen publicity and education,and form healthy and good living habits to shorten the number of days of hospitalization.The number of days of hospitalization should be shortened. 展开更多
关键词 STROKE Hospitalization costs Influencing factors
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部